Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I

Clinical Breast Cancer

Volumn 6, Issue 4, 2005, Pages 340-348

  Chernicky, Cheryl L ^a,b   Yi, Lijuan ^a,b   Tan, Huiqing ^a,b   Ilan, Judith ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen receptor; Invasion; MDA MB 435s breast cancer cells; Metastasis

Indexed keywords

ESTROGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; RNA 18S; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INVASION; CELL ASSAY; CELL INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; METASTASIS POTENTIAL; NORTHERN BLOTTING; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 28344448867     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.038     Document Type: Article

References (47)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
2. Thomas E, Hortobagyi GN. New paradigms in adjuvant systemic therapy of breast cancer. Endocrine-Related Cancer 2003; 10:75-89.
3. Yee D, Cullen KJ, Paik S et al. Growth regulation of human breast cancer by insulin-like growth factors. In: LeRoith D, Raizada MK, eds. Molecular and Cellular Biology of Insulin-like Growth Factors and Their Receptors. New York, NY: Plenum Press; 1989:237-245.
4. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mamm Gland Biol Neopl 1998; 3:85-94.
5. Hess KR, Pusztai L, Buzdar AU, et al. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003; 78:105-118.
6. Tiecher BA. Angiogenesis and cancer metastases: therapeutic approaches. Crit Rev Oncol Hematol 1995; 20:9-39.
7. Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39:93-102.
8. Hermanek P, Hutter RVP, Sobin LH, et al. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86:2668-2673.
9. Oh JS, Kucab JE, Bushel PR, et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002; 4:204-217.
10. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63:4384-4388.
11. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107:873-877.
12. Neuenschwander S, Roberts CT, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995; 136:4298-4303.
13. Chernicky CL, Yi L, Tan H, et al. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Therapy 2000; 7:384-395.
14. Chernicky CL, Tan H, Yi L, et al. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Mol Pathol 2002; 55:102-109.
15. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73:161-195.
16. Sandstrom M, Johansson M, Sandstrom J, et al. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression. Int J Dev Neurosci 1999; 17:473-481.
17. Meissauer A, Kramer MD, Hofmann M, et al. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp Cell Res 1991; 192:453-459.
18. Columbi M, Bellotti D, De Petro G, et al. Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells. Invasion Metastasis 1995; 15:22-33.
19. Alizadeh H, Ma D, Berman M, et al. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 1995; 14:449-458.
20. Paciucci R, Torà M, Diaz VM, et al. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 1998; 16:625-633.
21. Escaffit F, Estival A, Bertrand C, et al. FGF-2 isoforms of 18 and 22.5 kda differentially modulated-PA and PAI-1 expressions on the pancreatic carcinoma cells AR4-2J: consequences on cell spreading and invasion. Int J Cancer 2000; 85:555-562.
22. Burfeind P, Chernicky CL, Rininsland F, et al. Antisense RNA to the type I insulin-like growth factor I receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 1996; 93:7263-7268.
23. Brinkley BR, Beall PT, Wible LJ, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res 1980; 40:3118-3129.
24. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Molec Endocrinol 2000; 25:169-193.
25. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132:6-13.
26. Hankinson, SE, Willett WC, Coldita GA, et al. Circulating insulin-like growth factor-1 and the risk of breast cancer. Lancet 1998; 351:1393-1396.
27. Breast Disease in Pregnancy and Lactation. In: Bennett BB, Steinbach BF, Hardt NS, Haigh LS, eds. Breast Disease for Clinicians. New York, NY: McGraw-Hill; 2001:93-101.
28. O'Grady P, Lijinen HR, Duffy MJ. Multiple forms of plasminogen activator in human breast tumors. Cancer Res 1985; 45:6216-6218.
29. Yamashita J, Ogawa M, Inada K, et al. Breast cancer prognosis is poor when total plasminogen activator activity is low. Br J Cancer 1993; 67:374-378.
30. Pedersen AN Christensen IJ, Stephens RW, et al. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000; 60:6927-6934.
31. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact or urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94:116-128.
32. Gershtein ES, Kushlinskii NE. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exper Biol Med 2001; 131:67-72.
33. Escaffit F, Estival A, Bertrand C, et al. FGF-2 isoforms of 18 and 22.5 kDa differentially modulate t-PA and PAI-1 expressions on the pancreatic carcinoma cells AR4-2J: consequences on cell spreading and invasion. Int J Cancer 2000; 85:555-562.
34. Dunn SE, Torres JV, Nihei N, et al. The insulin-like growth factor-1 elevated urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy. Mol Carcinog 2000; 27:10-17.
35. Tranque P, Naftolin F, Robbins R. Differential regulation of astrocyte plasminogen activators by insulin-like growth factor-I and epidermal growth factor. Endocrinology 1994; 134:2606-2613.
36. Chernicky CL, Yi L, Tan H, et al. Differential regulation of plasminogen activators by insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) in ovarian cancer cells. Gynecol Oncol 2004; 92:454.
37. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200-207.
38. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852-1857.
39. Chernicky CL, Yi L, Tan H, et al. Differential regulation of tissue-type plasminogen activator (tPA) and invasion in metastatic human breast cancer cells exposed to epidermal growth factor (EGF) or insulin-like growth factor I (IGF-I). Proc Am Assn Cancer Res 2004; 45:41.
40. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83:249-289.
41. Alizadeh H, Ma D, Berman M, et al. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 1995; 14:449-458.
42. Koutsilieris M, Mitsiades C, Dimopoulos, T et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001; 86:5729-5736.
43. Cascinu S, Ferro ED, Grinati C, et al. Inhibition of tumour cell kinetics and serum IGF-I levels by octreotide in colorectal cancer patients. Gastroenterology 1997; 113:767-772.
44. Andrews DW, Resnicoff M, Flanders AE, et al. Results of a pilot study involving the use of an antisense oligodeocynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19:2189-2200.
45. Alonso DF, Farina HG, Skilton G, et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50:83-93.
46. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5:231-239.
47. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5:221-230.